After pregnancy, fetal cells remain in a woman's body for years. These cells may be involved in different physiological situations (e.g. wound healing) and diseases (e.g. cancer).The study will evaluate the level of circulating fetal immune cells in patients with breast cancer vs controls with benign breast tumors, and further characterize these fetal cells. Patients participation will be limited to accepting that an additional blood sample is collected on the day of their preop consultation and blood test.
Breast cancer is the most common cancer in the female population. The protective mechanism associated with pregnancy is not fully understood. During pregnancy fetal cells cross the placental barrier and may remain in the maternal circulation even for up to 30 years after childbirth. This phenomenon is called fetal microchimerism. The presence of circulating fetal cells would have a protective role against breast cancer. However, their phenotype and role in the anti-tumor response is not explored. The objective of the study is to identify the sub-population (s) of circulating fetal immune cells that may have an impact on the processes of carcinogenesis in breast cancer, in the context of fetal microchimerism.
Study Type
OBSERVATIONAL
Enrollment
80
As part of the treatment, 2 EDTA tubes of 10mL will be taken during a scheduled venipuncture as part of the preoperative assessment.
Hôpital de Tenon-Service de Gynécologie Obstétrique et Médecine de la Reproduction
Paris, France
Percentages of fetal cells in each immune cell subpopulation.
Using fluorescence activated cell sorting method.
Time frame: 3 years
Activation markers.
Using immunocytochemistry method.
Time frame: 3 years
Cytotoxicity markers.
Using immunocytochemistry method.
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.